Laura Gieldon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6559153/publications.pdf

Version: 2024-02-01

18	563	759233 12	839539 18
papers	citations	h-index	g-index

20	20	20	1300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
2	The landscape of chromothripsis across adult cancer types. Nature Communications, 2020, 11, 2320.	12.8	75
3	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	12.8	64
4	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
5	Diagnostic value of partial exome sequencing in developmental disorders. PLoS ONE, 2018, 13, e0201041.	2.5	36
6	Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	1.2	36
7	Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. BMC Cancer, 2019, 19, 396.	2.6	30
8	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
9	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers, 2019, 11, 809.	3.7	23
10	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
11	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. European Journal of Endocrinology, 2018, 178, K1-K9.	3.7	19
12	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
13	Skewed Xâ€inactivation in a family with DLG3â€associated Xâ€linked intellectual disability. American Journal of Medical Genetics, Part A, 2017, 173, 2545-2550.	1.2	12
14	Novel truncating PPM1D mutation in a patient with intellectual disability. European Journal of Medical Genetics, 2019, 62, 70-72.	1.3	10
15	Germline SDHBâ€inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes and Cancer, 2020, 59, 601-608.	2.8	4
16	Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2785-2789.	7.2	4
17	Germ cell mosaicism for AUTS2 exon 6 deletion. American Journal of Medical Genetics, Part A, 2021, 185, 1261-1265.	1.2	2
18	A frameshift mutation in BRCA1 leads to hereditary breast and ovarian cancer in one part of a family and to familial pancreatic cancer in another. Breast Cancer Research and Treatment, 2018, 167, 305-307.	2.5	1